Search

Your search keyword '"Knol, E. F."' showing total 558 results
Start Over Author "Knol, E. F."
558 results on '"Knol, E. F."'

2. IgE versus IgG and IgA: Differential roles of allergen‐specific antibodies in sensitization, tolerization, and treatment of allergies.

Author

Knol, E. F. and Neerven, R. J. J.

Abstract

Summary The prevalence of asthma, rhinitis, and food allergies has increased dramatically over the last few decades. This increase originally started in western countries, but is now also evident in many other regions of the world. Given the fact that the increase is so quick, the noted increase cannot be linked to a genetic effect, and many environmental factors have been identified that are associated with increased or reduced prevalence of allergies, like changing dietary habits, increased urbanization, pollution, exposure to microorganisms and LPS, and the farming environment and raw milk consumption. Although the key role of allergen‐specific IgE in allergies is well known, the role of allergen‐specific IgG and IgA antibodies is less well defined. This review will provide an overview of the functions of allergen‐specific IgE in allergy, the role of allergen‐specific antibodies (IgG (4) and IgA) in allergen immunotherapy (AIT), the possibility to use allergen‐specific antibodies for treatment of ongoing allergies, and the potential role of allergen‐specific antibodies in tolerance induction to allergens in a preventive setting. In the last, more speculative, section we will present novel hypotheses on the potential role of allergen‐specific non‐IgE antibodies in allergies by directing antigen presentation, Th2 development, and innate immune training. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology.

Author

Roth‐Walter, F., Adcock, I. M., Benito‐Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz‐Gracia, I., Knol, E. F., Jesenak, M., Levi‐Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C. A. M., and Stellato, C.

Subjects
LUNG diseases, CELLULAR aging, AGING, TASK forces, CHRONIC obstructive pulmonary disease
Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune‐driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence‐related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance

Author

Pascal, M., primary, Edelman, S. M., additional, Nopp, A., additional, Möbs, C., additional, Geilenkeuser, W. J., additional, Knol, E. F., additional, Ebo, D. G., additional, Mertens, C., additional, Shamji, M. H., additional, Santos, A. F., additional, Patil, S., additional, Eberlein, B., additional, Mayorga, C., additional, and Hoffmann, H. J., additional

Published
2023
Full Text
View/download PDF

5. EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance.

Author

Pascal, M., Edelman, S. M., Nopp, A., Möbs, C., Geilenkeuser, W. J., Knol, E. F., Ebo, D. G., Mertens, C., Shamji, M. H., Santos, A. F., Patil, S., Eberlein, B., Mayorga, C., and Hoffmann, H. J.

Subjects
BASOPHILS, TASK forces, QUALITY assurance, PEANUT allergy, DRUG allergy
Abstract

The article discusses the basophil activation test (BAT) as a diagnostic tool for managing patients with IgE-mediated allergies. The authors emphasize the need for standardization and external quality assurance (EQA) of laboratory protocols and results interpretation. A task force was created to develop a consensus protocol for BAT-EQA, and round robin tests were conducted to train participating laboratories. The article presents a proposed standard operating protocol for BAT and highlights the importance of EQA for routine implementation of the assay. The authors conclude that the consensus protocol provides acceptable inter- and intralaboratory variability and can be implemented across Europe. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. Cover Image

Author

Blankestijn, M. A., Otten, H. G., Suer, W., Weimann, A., Knol, E. F., and Knulst, A. C.

Published
2018
Full Text
View/download PDF

10. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

Author

Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A. R., Bergmann, K. C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, K. F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P. V., Aberer, W., Fink-Wagner, A. H., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J. P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O'Mahony, L., Knol, E. F., del Giacco, S., Chivato Pérez, T., Bousquet, J., Zuberbier, T., Akdis, C., and Jutel, M.

Subjects
Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Omalizumab, Dupilumab, Immunoglobulin E, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Reslizumab, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, Mepolizumab, biology, SARS-CoV-2, business.industry, Benralizumab, Telemedicine, 030228 respiratory system, chemistry, Immunology, biology.protein, Covid-19, business, medicine.drug
Published
2020

15. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Author

Bousquet, J., Akdis, C. A., Jutel, M., Bachert, C., Klimek, L., Agache, I., Ansotegui, I. J., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Del Giacco, S., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. -C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Ventura, M. -T., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Pawankar, R., Mubeccel, A., Mona, A. -A., Emilio, A. C., Hasan, A., Cristina, A. M., Zeinab, A., Mostafa, B. E., Sergio, B., Cristina, B., Eric, B., Bianca, B., Elisabeth, B., Larl-Christian, B., David, B., Leif, B., Attilio, B., Isabelle, B., Jacques, B., Louis-Philippe, B., Fulvio, B., Christopher, B., Roland, B., Carmen, B., Andrew, B., William, B., Fernan, C. -F., Davide, C., Silvia, C., Paulo, C., Walter, C., Vicky, C., Kai-Hakon, C., Warner, C., Thomas, C., Lorenzo, C., Alfonso, C. M., Niels, C., Ekaterine, C., George, C., Derek, C., Cemal, C., Giorgio, C., Ieva, C., Sousa Jaime, C. D., Maria del Carmen, C. D., Andre, C., Linda, C., Alvaro, C., Adnan, C., Ulf, D., Frederic, D. B., Diana, D., Pascal, D., Philippe, D., Alain, D., Ratko, D., Maria, D. C. T., Dejan, D., Ruta, D., Stephen, D., Patrik, E., Yehia, E. -G., Regina, E., Bieren Julia, E. -V., Alessandro, F., Wytske, F., Mina, G., Luis, G. R. J., Bilun, G., Sonya, G., Jose, G., Maximiliano, G., Maia, G., Ineta, G., Marta, G., Antonieta, G. M., Adnan, H., Elham, H., Jonathan, H., Martin, H., Yunuen, H. V., Guido, I., Carla, I., Zhanat, I., Edgardo, J., Ewa, J., Erika, J. -J., Sebastian, J., Guy, J., Ki-Suck, J., Jocelyne, J., Igor, K., Omer, K., Fuat, K., Przemyslaw, K., Jussi, K., Jorg, K. -T., Gerard, K., Marek, K., Mikael, K., Violeta, K., Amir, L., Susanne, L., Lan, L., Marcus, L., Michael, L., Jing, L., Philip, L., Brian, L., Karin, L. C., Bassam, M., Mika, M., Hans-Jorgen, M., Gailen, M., Pedro, M., Mohammad, M., Juan-Jose, M., Cem, M., Erik, M., Eli, M., Hans, M., Jean-Pierre, M., Florin, M., Neven, M., Branislava, M., Yousser, M., Mathieu, M., Mario, M. -A., Ralph, M., Lars, M., Antonella, M., Tihomir, M., Alla, N., Leyla, N. -B., Kristof, N., Laurent, N., Robyn, O., Kimihiro, O., Brian, O., Luigi, P. P., Isabella, P. -S., Petr, P., Nilos, P., Sim, P. H., Ruby, P., Ana, P., Bernard, P., Constantinos, P., Davor, P., Wolfgang, P., Todor, P., Fabienne, P., Paul, P., Lars, P., Emmanuel, P., Claus, R., Stella, R. M., Janet, R., Jose Angelo, R., Graham, R., Nicolas, R., Antonino, R., Jose, R. -P., Nelson, R., Lanny, R., Philip, R., Dermot, R., Mario, S. -B., Joaquin, S. -D., Glenis, S., Elie, S., Nikolaos, S., Estelle, S., Juan-Carlos, S., Dirceu, S., Talant, S., Manuel, S. -M., Cristiana, S., Rafael, S., Timo, S., Charlotte, S. U., Carel, T., Peter-Valentin, T., Massimo, T., Ioana, T., Marilyn, U. P., Erkka, V., Eric, V. G., Marianne, V. H., Olivier, V., Petra, V., Martin, W., Dana, W., Yun, W. D., Susan, W., Magnus, W., Dennis, W., Barbara, Y., Arzu, Y., Osman, Y., Mario, Z., Mihaela, Z., Beghe', Bianca, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, Helsinki University Hospital Area, Bousquet, J., Akdis, C., Jutel, M., Bachert, C., Klimek, L., Agache, I., Ansotegui, I. J., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Del Giacco, S., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Teresa Ventura, M., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Universitätsmedizin Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, CharitéHumboldt-Universität zu BerlinBerlin, Germany, University Hospital Montpellier, France, MACVIA-France, Montpellier, France, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wroclaw, Poland, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Center for Rhinology and Allergology, Wiesbaden, Germany, Transylvania University BrasovBrasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, NSW, Australia, Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Department of Biomedical Sciences, Humanitas University, MI, Pieve Emanuele, Italy, School of Medicine, University CEU San PabloMadrid, Spain, 3ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Montpellier, France, Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital 'Duilio Casula', University of Cagliari, Cagliari, Italy, Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, University of Science and Technology, Wuhan, Hubei, China, Center for research in health technologies and information systems- CINTESIS, Universidade do PortoPorto, Portugal, Allergy Unit, Instituto CUF Porto e Hospital CUF PortoPorto, Portugal, Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do PortoPorto, Portugal, Faculdade de Medicina da Universidade do PortoPorto, Portugal, Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Pathophysiology and Allergy Research, Medical University of ViennaVienna, Austria, Servicio de Alergia e Immunologia, Clinica Santa IsabelBuenos Aires, Argentina, Geneva, Switzerland, Departments of Immunology and Dermatology/Allergology, University Medical Center UtrechtUtrecht, Netherlands, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and HospitalMéxico City, Mexico, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain, Johns Hopkins School of Medicine, Baltimore, MD, United States, National Hospital Organization, Tokyo National HospitalTokyo, Japan, Dept of Otorhinolaryngology, Chiba University HospitalChiba, Japan, Departments of Medicine and Microbiology, University College Cork, Cork, Ireland, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of ManchesterManchester, United Kingdom, Allergy Dpt, Pediatric Clinic, University of Athens, Athens, Greece, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Germany, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland, Centre for Inflammation Research, Child Life and Health, University of Edinburgh, Edinburgh, United Kingdom, University of Bari Medical School, Unit of Geriatric ImmunoallergologyBari, Italy, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine &, Institute of Health SciencesVilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Celal Bayar University, Department of PulmonologyManisa, Turkey, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and AllergyBerlin, Germany, AII - Inflammatory diseases, and Ear, Nose and Throat

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Statement (logic), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, education, medicine.disease_cause, Article, corticosteroids, 03 medical and health sciences, 0302 clinical medicine, Allergic, Adrenal Cortex Hormones, Administration, Intranasal, Humans, SARS-CoV-2, COVID-19, Rhinitis, Allergic, medicine, Immunology and Allergy, biologics, 030223 otorhinolaryngology, Coronavirus, Rhinitis, business.industry, chronic rhinosinusitis, allergy, 3. Good health, 030228 respiratory system, Intranasal, 3121 General medicine, internal medicine and other clinical medicine, Administration, Nasal administration, business
Published
2020

38. A major gene for host response to porcine reproductive and respiratory syndrome is not unfavorably associated with overall performance under nonchallenging conditions in commercial pig lines1

Author

Dunkelberger, J. R., Mathur, P. K., Lopes, M. S., Knol, E. F., and Dekkers, J. C. M.

Subjects
Male, disease, Genotype, Swine, Animal Genetics and Genomics, Porcine Reproductive and Respiratory Syndrome, swine, porcine reproductive and respiratory syndrome virus, WUR10000125, Stillbirth, Eating, Parity, Phenotype, Pregnancy, Animals, Lactation, Female, Porcine respiratory and reproductive syndrome virus, Alleles
Abstract

A QTL for host response to porcine reproductive and respiratory syndrome (PRRS) was identified in a previous study. The SNP WUR10000125 (WUR) is used as a tag SNP for this QTL. The favorable (B) allele at this SNP is in low frequency in commercial populations, possibly because this allele is unfavorably associated with an important trait under nonchallenging conditions and, therefore, may have been selected against. Therefore, objectives of this study were to estimate the effect of WUR on traits under selection in commercial lines under nonchallenging conditions and to estimate the effect of WUR genotype of parents on performance of crossbred progeny in a commercial-like environment. Data were collected on 4 purebred lines: a Landrace dam line (D1), a Large White dam line (D2), a synthetic sire line (S1), and a Pietrain sire line (S2). Traits analyzed included total number born, number stillborn, farrowing survival, lactation survival, litter mortality, daily feed intake (DFI), backfat, average test daily gain (TGR), average lifetime daily gain (LGR), and Topigs Norsvin selection index (TSI) value, indicative of overall economic value. Deregressed EBV were calculated for each trait (except TSI) and analyzed within line. In the S1 line, AB and BB pigs had significantly lower TGR (P = 0.002) and LGR (P = 0.001) than AA pigs but also lower DFI (P = 0.004). Conversely, AB and BB pigs had significantly higher DFI (P < 0.001) and AB pigs had significantly higher TGR (P = 0.03) than AA pigs in the S2 line. The effect of WUR on TSI was not significant for any line (P ≥ 0.15). Analyses of phenotypic records collected on crossbred progeny of S1 sires and D1 × D2 F1 females showed no significant effect of parent WUR genotype on DFI, backfat, TGR, or LGR (P ≥ 0.07). In conclusion, the effect of WUR was nonsignificant for most traits but the magnitude and direction of the effect differed by trait and by line. The favorable allele for host response to PRRS was associated with greater DFI and a tendency for greater TGR in the S2 line, but the opposite direction of effect was detected for the S1 line. Regardless of the effect on individual traits, no significant effect of WUR on TSI was detected for any line. Therefore, selecting for the B allele is expected to result in progeny with increased resistance to PRRS without compromising overall economic value under normal, nonchallenging conditions.

Published
2017

40. Specifieke allergenen bij de diagnostiek van pinda-allergie

Author

van Erp, Francine C., Le, T. M., Kansen, H. M., Meijer, Y., van der Ent, C. K., Knol, E. F., and Knulst, A. C.

Subjects
Component-resolved diagnostics, Peanut, Infectious Diseases, SIgE, food and beverages, Critical Care and Intensive Care Medicine
Abstract

Self-reported peanut allergy is common and has a major impact on quality of life. It is therefore important to accurately diagnose or exclude peanut allergy. Recent publications have shown that using specific IgE to a peanut component (Ara h 2) can optimize the diagnostic work-up in patients with suspected peanut allergy. In this article, we describe the use of these component-resolved diagnostics in daily practice based on three children with suspected peanut allergy. The presented flowchart based on Ara h 2 can improve the diagnostic flow of children with suspected peanut allergy and prevent unnecessary double blind placebo controlled food challenges.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results